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Abstract To date limited data are available to predict the
progression to end-stage heart failure (HF) with subsequent
death (non-SCD), need for heart transplantation, or sudden
cardiac death (SCD) in children with hypertrophic car-
diomyopathy (HCM). We aimed to determine predictors of
long-term outcome in children with HCM. A total of 112
children (median 14.1, IQR 7.8–16.6 years) were followed
up for the median of 6.5 years for the development of
morbidity and mortality, including arrhythmic and HF-re-
lated secondary end points. HF end point included HF-
related death or heart transplant, and arrhythmic end point
included resuscitated cardiac arrest, appropriate ICD dis-
charge, or SCD. Overall, 23 (21 %) patients reached the
pre-defined composite primary end point. At 10-year fol-
low-up, the event-free survival rate was 76 %. Thirteen
patients (12 %) reached the secondary arrhythmic end
point, and 10 patients (9 %) reached the secondary HF end
point. In multivariate model, prior cardiac arrest
(r = 0.658), QTc dispersion (r = 0.262), and NSVT
(r = 0.217) were independent predictors of the arrhythmic
secondary end point, while HF (r = 0.440), LV posterior
wall thickness (r = 0.258), LA size (r = 0.389), and
decreased early transmitral flow velocity (r = 0.202) were
all independent predictors of the secondary HF end point.
There are differences in the risk factors for SCD and for
HF-related death in childhood HCM. Only prior cardiac
arrest, QTc dispersion, and NSVT predicted arrhythmic
outcome in patients aged\18 years. LA size, LV posterior
wall thickness, and decreased early transmitral flow
velocity were strong independent predictors of HF-related
events.
Keywords Hypertrophic cardiomyopathy  Sudden
cardiac death  Cardioverter–defibrillator  Heart failure 
Heart transplant  Children
Introduction
Hypertrophic cardiomyopathy (HCM) is a relatively com-
mon genetic cardiac disease, and it accounts for 42 % of
childhood cardiomyopathy [14]. The severity of cardiac
hypertrophy, etiology, and the clinical course of HCM in
children are varied, resulting in a large spectrum of clinical
and phenotypic expressions [3, 14, 16, 21, 23, 27, 35, 37].
Importantly, HCM is the most common cause of sudden
cardiac death (SCD) in the young (including competitive
athletes) [9, 18]. According to previous studies, the inci-
dence of SCD in children with HCM ranges from 1 [3, 27]
to 6 % [8, 32, 33]. However, limited data are available to
predict which children will progress to end-stage heart
failure (HF) with subsequent death or need for heart
transplantation (HT) or who will die from SCD [4, 37].
Specific risk factors for SCD in adults with HCM have
been proposed [6, 9, 11, 17, 38], while a few series have
been focused on children [5, 15, 20, 24, 31, 33, 34, 37].
The aim of this study was to determine predictors of
long-term outcome in children with HCM including known
adult risk factors for SCD and previously proposed pedi-
atric risk factors for death. Moreover, we distinguish both
arrhythmic and heart failure end points to determine
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From May 1993 to January 2014, pediatric patients with
diagnosed HCM hospitalized in the Department of Pedi-
atric Cardiology of the Children’s Memorial Health Insti-
tute were prospectively enrolled. Criteria for inclusion in
the study were age\18 years at the time of diagnosis and
echocardiographic evidence of LV hypertrophy defined as
a diastolic septal thickness or LV diastolic wall thickness
z-score[2 (determined as more than two standard devia-
tions from the mean value for the population corrected for
body surface area (BSA) [10, 12], in the absence of
hemodynamic conditions that could account for the
observed hypertrophy. The study also included patients
with syndrome-associated HCM. The institutional ethics
committee approved this study. Informed consent was
obtained from all individual participants included in the
study.
Data Collection
Patients demographics, clinical symptoms, family history
of HCM and SCD, treatment strategy as well as the results
of echocardiography, 12-leads ECG, 24-h Holter ECG,
exercise test with assessment of blood pressure response to
exercise were collected. Cardiac examination was repeat-
edly performed during the follow-up period. For the anal-
ysis, the most recent results or the later results before the
end point were chosen. The period from the diagnosis of
HCM to the most recent study ranged from 1 month to
17.3 years, median 2.7 (0.89–5.83) years. Since 2005, each
patient was also screened for metabolic disorders (the
metabolic tests were performed in 92 patients). Since 2010
the possibility of genetic testing occurred in individual
cases. In addition, pacemaker or implantable cardioverter–
defibrillator (ICD) placement, septal myectomy, and HT
were recorded.
Family history of SCD (FHSCD) was defined as rec-
ommended in the literature [10]. Unexplained syncope was
defined as unexplained transient loss of consciousness at or
prior to first evaluation. Two-dimensional, Doppler, and
M-mode echocardiography were performed at rest using
standard methods. Echocardiographic measurements
included septal wall thickness (SWT) and LV posterior
wall thickness (LVPWT) (mm, z-score), LA size (mm,
z-score), and the presence of LV outflow tract obstruction
(LVOTO). LA dimension was measured at end-systole as
the anteroposterior linear diameter from the parasternal
long-axis view. LA enlargement was defined as z-score[2
[12]. The SWT, LWPWT in diastole, and the LA dimen-
sion were evaluated for each patient and indexed to the
patient’s BSA as recommended in the literature [12].
Z-scores for the SWT, LVPWT, and the LA dimension
were calculated using the formula for z-scores as reported
in the literature [2] with the use of the calculator given on a
website [12, parameterz.com]. Sustained monomorphic
ventricular tachycardia (SVT), non-sustained ventricular
tachycardia (NSVT), and an abnormal blood pressure
response to exercise (ABPRE) were defined as recom-
mended in the literature [10]. In all patients, cardiac tests
results and data from the family history were collected and
analyzed regarding the presence of reported adult risk
factors for SCD [11, 17, 38]. In addition, in all patients
previously published risk factors for death specific to the
pediatric population such as SWT cutoff of [20 mm,
SWT[ 190 % of upper normal limit for age, QTc dis-
persion, LVPW-to-cavity ratio [0.30, restrictive physiol-
ogy, and age at diagnosis of HCM were analyzed.
Moreover, the LA size was calculated and its relevance as a
risk factor for death in children with HCM was analyzed.
Events Data
Patient events were recorded by communication with
children’s parents. Medical records were reviewed after
attendance in outpatient clinics or hospital stay. No patient
was lost to follow-up.
The pre-specified primary end point was the composite
of cardiovascular death, resuscitated cardiac arrest (CA)
due to SVT or VF, appropriate ICD discharge or a HT as
previously published [29]. Two separate secondary end
points were predefined: A composite heart failure (HF) end
point included HF-related death or HT; a composite
arrhythmic end point included resuscitated CA due to SVT
or VF, appropriate ICD discharge, or SCD. Patients were
censored at the time of their first event or at the time of
their last clinical follow-up.
Statistics
Statistical analysis was performed using MedCalc statisti-
cal software (version 12.4, MedCalc Software, Ostend,
Belgium) and SPSS software. Results are presented as
median (IQR) values. Nominal variables are expressed as
number of subject and the percent in the analyzed group.
Comparisons of demographic and clinical characteristics
between patients with and without end points were made
with unpaired t test or Chi-square tests for continuous and
categorical data, respectively.
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Demographic, clinical, and scan characteristics were all
first tested with univariate analysis using Cox proportional
hazards model, and then all variables were taken forward to
be considered for inclusion in the multivariate model. In
addition, all risk factors (both proposed adult and proposed
pediatric ones) were tested separately with univariate
analysis for the compound arrhythmic end point and the
compound heart failure end point to identify statistical
significance of each variable, and then all variables were
included in the multivariate model. The model was con-
structed with a forward selection procedure, with any
variable that improved the likelihood ratio test statistic by
an amount equivalent to p\ 0.05 included. Eigenvalues
and canonical correlation analysis were used to calculate
the included variables participation in the variability of the
response variable. The canonical variable was calculated,
and the parameters the most responsible for the observed
variability of the composite end point had the highest
correlation value. Correlations above 0.2 indicated statis-
tically significant parameters (correlation coefficient
r C 0.2). The statistical significance of multivariate anal-
ysis for the composite secondary arrhythmic and heart
failure end point was demonstrated using an assay Pillais.
Furthermore, relative risk indicators for all variables were
calculated, based on the cutoff points assessed based on the
comparison of frequency of distribution.
Results
Baseline Characteristics
A total of 112 patients with HCM were recruited between
May 1, 1993 and January 31, 2014, the median age was
14.1 (7.8–16.6) years, 60 % male. Patients were followed
prospectively for the median of 6.5 (2.9–9.6) years. Clin-
ical characteristics of the patient population are presented
in Table 1.
Genetic syndrome-associated HCM was diagnosed in
eight patients (in four patients Leopard syndrome, in two
patients Noonan, in one patient Costello and in one patient
Kabuki syndrome). Inborn metabolic syndrome was diag-
nosed in four children (mitochondrial cytopatia in two
patients, Pompe disease in one patient and type III glyco-
gen storage in one patient).
Outcomes
During follow-up, there were 13 (11.6 %) cardiovascular
deaths, six of which occurred suddenly and seven deaths
were due to HF. Overall 23 (21 %) patients reached the
composite primary end point (13 patients died, three
children had a HT due to progressive heart failure, five
children had appropriate ICD discharge and two survived
resuscitated CA). Kaplan–Meier survival analysis shows
86 % event-free survival rate at 5 years and 76 % event-
free survival rate at 10-year follow-up (Fig. 1a).
Thirteen patients (12 %) reached the secondary
arrhythmic end point. Overall 10 of 112 patients (9 %)
reached the secondary HF end point: one of 88 (1.1 %)
with the LA size of\3 z-score and eight of 13 (61.5 %)
with LA size of C3 z-score (log rank p\ 0.0001; Fig. 1b).
In the study group, no patient had both an arrhythmic
and a HF end point. The median age of children at the time
of arrhythmic end points was 13.8 (11.8–16.3) years, ran-
ged from 0.5 to 22 years. The median age of patients at the
time of the HF end points was 9.8 (6.8–16) years, ranged
from 1.9 to 16.7 years. The age profile of patients that
reached arrhythmic end point and HF end point was
illustrated in a Fig. 2.
Risk Factors for Primary and Secondary Outcomes
The frequency of reported adult risk factors for SCD and
risk factors for death in children with HCM presented by
other authors is summarized in Table 2. In our group of
patients, no sustained ventricular tachycardia (SVT) or
ventricular tachycardia (VT) not requiring resuscitation
occur. In our patients, episodes of non-sustained ventricular
tachycardia (NSVT) occured, which was regarded as a risk
factor for sudden cardiac death, but it was not considered
as a primary end point or as an arrhythmogenic secondary
end point.
In univariate analysis previous CA (p = 0.004; sensi-
tivity 13.04; 95 % CI 2.8–33.6; specificity 100; 95 % CI
95.9–100; PPV 100; 95 % CI 29.2–100; NPV 81.7; 95 %
CI 73.0–88.4), the gradient value in the LVOT (p = 0.04;
sensitivity 91.3; 95 % CI 72–98.9; specificity 43.82; 95 %
CI 33.3–54.7; PPV 29.6; 95 % CI 19.3–41.7; NPV 95.1;
95 % CI 83.5–99.4), QTc dispersion (p = 0.0042; sensi-
tivity 56.52; 95 % CI 34.5–76.8; specificity 77.53; 95 % CI
67.4–85.7; PPV 39.4; 95 % CI 22.7–58.2; NPV 87.3; 95 %
CI 78.0–93.8), HF at presentation (p = 0.0003; sensitivity
43.48; 95 % CI 23.2–65.5; specificity 94.38; 95 % CI
87.4–98.2; PPV 66.7; 95 % CI 38.4–88.2; NPV 86.6; 95 %
CI 78.2–92.7), LA size z-score (p = 0.001; sensitivity
77.78; 95 % CI 52.4–93.6; specificity 59.04; 95 % CI
47.7–69.7; PPV 29.2; 95 % CI 16.8–44.2; NPV 92.5; 95 %
CI 81.8–97.9), LVPW-to-cavity ratio [0.3 (p = 0.03;
sensitivity 43.5; 95 % CI 23.2–65.5; specificity 78.65;
95 % CI 68.7–86.6; PPV 34.5; 95 % CI 17.7–54.7; NPV
84.3; 95 % CI 74.7–91.4) and early mitral flow velocity
(mitral E vel.) median value (p = 0.04; sensitivity 64.7;
95 % CI 38–85; specificity 84.5; 95 % CI 75–91.5; PPV
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Table 1 Patient characteristics
Clinical parameters Study group n = 112 patients
Age at clinical evaluation
Cohort median, years (IQR) 14.1 (7.8–16.6)
Age B 1 3 (2.7)
Age[ 1 and B5 8 (7.1)
Age[ 5 and B10 25 (22.3)
Age[ 10 and\18 76 (67.9)
Age at diagnosis HCM
Cohort median, years (IQR) 4.83 (0.54–11)
Age B 1 38 (33.9)
Age[ 1 and B5 21 (18.8)
Age[ 5 and B10 21 (18.8)







Chest pain 34 (30.4)
Syncope 17 (15.2)
Dyspnoea on exertion 24 (21.4)
Resuscitated sudden death 3 (2.7)
Palpitations 22 (19.6)
Heart failure (NYHA III–IV) 20 (17.9)
Follow-up, years
Median (IQR) 6.5 (2.9–9.6)
Death 13 (11.6)
Heart failure death 7 (6.2)
SCD 6 (5.4)
ICD appropriate discharge 5 (4.5)
Resuscitated cardiac arrest 2 (1.8)
NSVT 17 (15.2)
Heart transplant 3 (2.7)
Echocardiographic data at last follow-up
Left ventricular morphology
Asymmetric septal hypertrophy 78 (69.6)
Concentric LV hypertrophy 31 (27.7)
Apical LV hypertrophy 3 (2.7)
Septal wall, mm 15.3 (11–21.2)
Septal wall, z-score 7.8 (4.9–15.1)
Posterior wall, mm 8.7 (7.3–11.5)
Posterior wall, z-score 1.6 (0.07–3.5)
LA size, mm 34.3 (26.4–45)
LA size, z-score 1.7 (0.6–5.1)




Antiarrhythmics (sotalol or amiodarone) 9 (8.0)
ACE inhibitors 9 (8.0)
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45.8; 95 % CI 25.6–67.2; NPV 92.2; 95 % CI 83.8–97.1)
and z-score (p = 0.027; sensitivity 64.71; 95 % CI
38.3–85.8; specificity 83.33; 95 % CI 73.6–90.6; PPV 44;
95 % CI 24.0–65.5; NPV 92.1; 95 % CI 83.6–97.0) pre-
dicted primary outcome.
We also looked for the optimal cutoff point for the risk
of primary end point in our study group. The cutoff points
for each risk factor for the primary end point and the value
of relative risk are summarized in Table 2 and in selected
Figs. 3, 4, 5 and 6.
The univariate analysis was separately performed for the
compound arrhythmic end point and the compound HF end
point. Only prior CA (p\ 0.001; sensitivity 23.08; 95 %
CI 5–53.8; specificity 100; 95 % CI 96.3–100; PPV 100;
95 % CI 29.2–100; NPV 90.8; 95 % CI 83.8–95.5) and
QTc dispersion (p = 0.034; sensitivity 46.15; 95 % CI
19.2–74.9; specificity 79.8; 95 % CI 70.5–87.2; PPV 23.1;
95 % CI 8.8–44.1; NPV 91.9; 95 % CI 83.9–96.7) pre-
dicted arrhythmic secondary end point. NSVT showed a
trend toward statistical significance (p = 0.078; sensitivity
30.77; 95 % CI 9.1–61.4; specificity 86.87; 95 % CI
78.6–92.8; PPV 23.5; 95 % CI 6.5–50.8; NPV 90.5; 95 %
CI 82.8–95.6) for predicting arrhythmic secondary end
point. Heart failure (p\ 0.001; sensitivity 80; 95 % CI
44.4–97.5; specificity 93.14; 95 % CI 86.4–97.2; PPV
53.3; 95 % CI 25.7–79.5; NPV 97.9; 95 % CI 92.9–99.8),
LVPWT z-score (p = 0.001; sensitivity 70; 95 % CI
34.8–93.3; specificity 57.84; 95 % CI 47.7–67.6; PPV 14;
95 % CI 5.8–26.7; NPV 95.2; 95 % CI 86.5–99.0), LVPW-
to-cavity ratio [0.3 (p = 0.052; sensitivity 60; 95 % CI
26.2–87.8; specificity 77.45; 95 % CI 68.1–85.1; PPV
20.7; 95 % CI 7.8–40.1; NPV 95.2; 95 % CI 88.1–98.7),
LA size (p = 0.041) and LA size z-score (p\ 0.001;
sensitivity 83.33; 95 % CI 35.9–99.6; specificity 93.68;
95 % CI 86.8–97.6; PPV 45.5; 95 % CI 15.6–78; NPV
98.9; 95 % CI 93.9–100.0), mitral E vel. (p = 0.027) and
mitral E vel. z-score (p = 0.008; sensitivity 80; 95 % CI
28.4–99.5; specificity 86.46; 95 % CI 78–92.6; PPV 23.5;
95 % CI 6.5–50.8; NPV 98.8; 95 % CI 93.5–100.0) pre-
dicted secondary HF end point in univariate model.
In the multivariate canonical analysis, only prior CA
(r = 0.658), OTc dispersion (r = 0.262), and NSVT
(r = 0.217) were explaining the variance of the arrhythmic
secondary outcome. For the secondary HF outcome heart
failure (r = 0.440), LA size z-score (r = 0.389), LVPWT
z-score (r = 0.258) and mitral E vel. z-score (r = 0.202)
explained the variance of the end point in multivariate
canonical analysis.
Table 1 continued
Clinical parameters Study group n = 112 patients
Diuretics (furosemide or spironolactone) 34 (30.3)
Myectomy 8 (7.1)
ICD implantation 21 (18.8)
Primary prevention 15 (13.4)
Secondary prevention 6 (5.4)
Data expressed as median (IQR) or frequencies (percentages)
Fig. 1 a Event-free survival for the study group. b Heart failure-free
survival for patients with LA size\3 z-score and C3 z-score (log rank
p\ 0.0001)




The clinical characteristic of our study group remains
comparable to the previously described cohorts [1, 3, 5, 24,
27]. In the study group 21 % of patients reported fatigue or
dyspnea on exertion, which is in concordance with previ-
ously reported rates (14–24 %) [5, 27]. Similar to other
studies 30 % of children complained of chest pain and
20 % complained of palpitations [3]. Should be noted that
as many as 18 % of children presented with symptomatic
HF (NYHA class III and IV) which exceeds the frequency
presented by other authors [15, 31]. It should be stressed
that children under 1 year of age at diagnosis of HCM
constituted 34 % of our group. Furthermore eight (7 %)
patients had coexisting genetic syndrome (Noonan, Leop-
ard, Costello and Kabuki), and four patients (3.5 %) had
inborn metabolic disorders (mitochondrial cytopathy,
Pompe and type III glycogen storage disease). Among
eight patients with an underlying genetic syndrome, two
(25 %) children reached the composite heart failure end
point (HF-related death in one patient with Noonan and HT
in one patient with Leopard syndrome). Out of four chil-
dren with inborn metabolic disorders, in one (25 %) patient
a composite arrhythmic end point occurred (resuscitated
CA in child with mitochondrial cytopathy).
Alike in previous studies [5, 7] in 3 % of patients, the
prior resuscitated sudden cardiac death was their presenting
symptom. It should be stressed that almost half of the
children (43 %) had a family history of HCM in at least
one family member, while in other studies familial inci-
dence of HCM ranged from 17 to 43 % [3, 5, 11]. Also,
there was a higher incidence of FHSCD due to HCM (22 %
in the analyzed group of children vs 17 % in other study)
[5].
Left Atrial Size
This is the first prospective study to demonstrate the value
of LA size on echocardiography to independently predict
outcome in children with HCM. Previously, marked LA
enlargement has been reported to predict outcome in adult
patients with HCM [36] but not in children. In the study by
Nistri et al. LA size of more than 48 mm (the 75th per-
centile) increased the risk of HF-related death by 3.1 but
was unassociated with SCD [26]. Other study demonstrated
the potential clinical importance of LA volume index in
pediatric HCM as a marker of the severity of underlying
diastolic dysfunction, symptom score and decreased exer-
cise capacity [22]. In the study by Maskatia et al. [20]
restrictive physiology, defined as LA enlargement, E/E0
ratio at least 10 or E/A ratio[3 correlated with all-cause
cardiac death or aborted SCD in childhood HCM. The
results of our study demonstrated that LV diastolic dys-
function expressed by decreased mitral E vel. was associ-
ated with HF-related unfavorable prognosis. In our study
LA size was an independent predictor of both the primary
end point and secondary HF-related outcome. Just like in
the study by Nistri et al. [25], the results of our research
have shown that LA enlargement predicted HF-related
unfavorably outcome and was not associated with SCD.
Patients with LA size of\3 z-score were much less likely
to suffer from HF-related end points than patient with LA
enlarged above 3 z-score.
Adult Risk Factors
We found that among known adult risk factors previous
CA was an independent predictor of both primary end point
and secondary arrhythmic outcome in children with HCM.
It is worth emphasizing the fact that NSVT was a statisti-
cally significant predictor of the arrhythmic secondary
Fig. 2 Age spectrum of
arrhythmic and heart failure end
points in children with
hypertrophic cardiomyopathy
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Table 2 Prevalence of adult risk factors for sudden death and previously reported pediatric risk factors for death in the study group





end point (n = 89)
Patients with primary




RR (95 % CI)
Family history of SCD (22 %) 25/112 20 5 0.84 – 0.967
(0.399–2.343)
Prior cardiac arrest (3 %) 3/112 0 3 0.004 – 5.450 (3.668–
8.098)
Syncope (15 %) 17/112 14 3 0.99 – 0.838
(0.280–2.514)
NSVT (15 %) 17/112 11 6 0.19 – 1.972
(0.909–4.279)
Extreme LVH C 30 mm
(8.9 %)
10/112 8 2 0.71 – 0.971
(0.266–3.553)
ABPR to exercise (31 %) 22/70 17/62 5/8 0.11 No cutoff 0.439
(0.224–0.859)
LVOTO C 30 mmHg (25 %) 28/112 20 8 0.34 No cutoff 1.600
(0.760–3.367)
LVOT gradient, mmHg 112 6.8 (5–19) 10.9 (7–31.4) 0.04 No cutoff –
Age at diagnosis, years 112 5 (0.6–12) 4 (0.2–10) 0.48 No cutoff –
SWT, mm 112 14.9 (11.1–21.2) 16.5 (10.3–20) 0.94 30 1.922
(0.292–12.657)
SWT, z-score 112 7.6 (4.7–14.9) 11.3 (5.6–16.8) 0.37 7 0.856
(0.410–1.788)
LVPWT, mm 112 8.6 (7.2–11.3) 9.6 (7.4–11.8) 0.39 10 1.315
(0.636–2.719
LVPWT, z-score 1.4 (0.1–3.2) 3 (0.1–6.3) 0.068 4 2.488
(1.234–5.013)
SWT of[20, mm (26.8 %) 30/112 25 5 0.54 – 0.759
(0.309–1.864)
SWT expressed as percent of
95th centile value for age
112 146.9 (116.7–219.1) 181.6 (125.8–222.2) 0.72 195 0.680
(0.330–1.402)
SWT[ 190 % of upper normal
limit for age (38.4 %)
43/112 32 11 0.3 – 1.471
(0.713–3.034)
QTc dispersion 112 0.04 (0.04–0.06) 0.06 (0.04–0.06) 0.0042 0.055 3.153 (1.506–
6.603)
QTc 112 0.41 (0.38–0.43) 0.42 (0.39–0.45) 0.27 0.415 1.214
(0.586–2.518)
Heart failure at presentation
(17.9 %)
20/112 10 10 0.0003 – 3.538 (1.815–
6.899)
LA size, mm 112 34 (25.7–44.4) 39 (33–47) 0.1 38 2.496
(1.184–5.262)
LA size, z-score 1.57 (0.34–3.82) 4.8 (2.2–8.2) 0.001 3 3.125 (1.450–
6.736)




29/112 19 10 0.03 – 2.202 (1.085–
4.468)
E/A, cm/s 101/112 1.56 (1.25–1.9) 1.39 (1.03–1.55) 0.24 3 1.516
(0.262–8.770)
E/A, z-score -0.72 (-1.19) to
(-0.27)
-1 (-1.57) to (-0.78) 0.16 1 1.753
(0.596–5.155)
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outcome in multivariate analysis in the studied group. The
results of study by Monserrat et al. are similar, showing
that the risk of SCD is significantly higher in younger
(\ 30 years of age) patients with NSVT on Holter ECG
[22]. It should be emphasized that the current European
Society of Cardiology (ESC) guidelines include NSVT into
a major risk factors for SCD in children with HCM [10].
The fact that FHSCD was not a risk factor for SCD in
childhood HCM in the studied group deserves a special
attention. The later seems to be very important because, in
the opinion of some authors, it would be reasonable to
implant an ICD with only one risk factor, for example
FHSCD [11]. Although risk factors in adult have been well
described [9, 11, 17, 38], it seems that they suboptimally
differentiate patients at high and low risk of SCD [28, 30].
Therefore, the ICD implantation should be planned with
Table 2 continued





end point (n = 89)
Patients with primary




RR (95 % CI)
E vel, cm/s 101/112 85.2 (73.8–97) 63 (46–91) 0.04 70 0.220 (0.090–
0.538)
E vel, z-score -0.5 (-1) to (0.31) -1.94 (-2.4) to
(-0.25)
0.027 -1 0.265 (0.107–
0.653)
Bold values indicate statistically significant data
Data expressed as median (IQR) or frequencies (percentages). No cutoff = frequency distribution similar, no cutoff point can be assessed
LV Left ventricular, LA left atrial, E vel early mitral inflow E velocity, E/A early mitral inflow E to late mitral inflow A ratio, SCD sudden cardiac
death, NSVT non-sustained ventricular tachycardia, LVH left ventricular hypertrophy, SWT septal wall thickness, LVPWT left ventricular
posterior wall thickness, ABPR abnormal blood pressure response, LVOTO left ventricular outflow tract obstruction
Fig. 3 Left ventricular
posterior wall thickness z-score
for patients with and without
primary end point, cutoff point
value C4
Fig. 4 Left atrial size z-score
for patients with and without
primary end point, cutoff point
value C3
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great caution, especially in pediatric population [13, 19].
The current ESC guidelines [10], in addition to recom-
mended so far major risk factors for SCD, take into account
additional risk factors for SCD in adults such as LA size,
patient age, and LVOTO. These parameters allow more
individualized risk prediction on which clinical decisions
can be made.
Pediatric Risk Factors
Very few series focused on the evaluation of risk factors
for death in children with HCM. Predictors such as
hypertrophy (wall thickness z-score [6) and ABPR to
exercise [5] or a SWT more than 190 % of upper limit for
age, and/or QRS amplitude sum of more than 10 mV on
limb lead ECG [31, 33], SWT cutoff of[20 mm [31], QTc
dispersion [37] have been previously reported as indepen-
dent risk factors for HF-related death or SCD in small
populations. The study by Ostman-Smith, which showed
that risk factors for SCD and for HF-related death are not
the same in childhood HCM, demonstrated that Noonan
syndrome and generalized cardiac hypertrophy with a
LVPW-to-cavity ratio [0.30 were risk factors for HF-
related death [31]. The results of our study are consistent
with the above cited publication [31]. Risk factors for SCD
and HF-related death differ in our pediatric population with
HCM. Heart failure, LVPWT, LA size, and decreased
mitral E vel. were independent predictors of the secondary
HF outcome in multivariate analysis but were unassociated
with SCD. Interestingly, in our pediatric cohort LVPW-to-
cavity ratio [0.3 demonstrated to predict secondary HF
outcome in univariate analysis but not in the multivariate
model.
In the study by Moak et al. [24] traditional adult risk
factors such as FHSCD, VT on Holter and exercise-in-
duced hypotension did not predict events, whereas SWT at
least 20 mm and inducible VT on electrophysiological
study did. In another study by Yetman et al. [37] increased
QTc dispersion on baseline ECG was significantly associ-
ated with an increased risk of SCD what was also
demonstrated in our pediatric cohort. QTc dispersion pre-
dicted both primary end point and secondary arrhythmic
outcome both in univariate and multivariate model. In our
studied group risk factors for SCD and secondary
arrhythmic outcome such as prior CA, QTc dispersion, and
NSVT were not associated with HF-related end point.
Fig. 5 Early transmitral flow
velocity (E) z-score for patients
with and without primary end
point, cutoff point value B-1
Fig. 6 QTc dispersion for
patients with and without
primary end point, cutoff point
value C0.055
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We found an 86 % event-free survival rate at 5 years and
76 % event-free survival rate at 10-year follow-up. The
overall mortality in our cohort was 11.6 %, which is sim-
ilar to that of 11.4 % (11 deaths in 96 patients) reported by
Decker et al. [5]. In our study HF-related deaths occurred
almost as frequent as SCD (6.2 vs 5.4 %), what remains in
keeping with previous reports [5, 31, 37]. Interestingly, the
HF—free survival rate was 92 % at 5-year follow-up and
85 % at 10 years, which is in keeping with previous data
[33]. The results of our study demonstrated that patients
with arrhythmic end point were older than children with
heart failure end point.
Conclusions
The risk factors for sudden death and for heart failure-
related death are different in childhood HCM. Only prior
CA, QTc dispersion and NSVT predicted arrhythmic out-
come in patients of \18 years of age. LA size, LVPWT,
and decreased mitral E velocity were strong independent
predictors of heart-failure-related events. The prediction of
clinical outcome in children with HCM still remains a
challenge and should be the subject of large-scale multi-
center trials.
No association between the medications and end points
has been found in our study. It seems reasonable to
maintain the current clinical practice with special caution
in patients with risk factors for both heart failure and
arrhythmic end points.
Limitations
The main limitation of our study is a lack of genetic testing,
which has become more widely available just recently. The
risk factors for both primary and secondary end points can
possibly vary in different genetic conditions. Further
studies with genetics provided are required.
Secondly, we included patients with an underlying
syndrome what made our study group less homogenous.
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